Conference Coverage

Results Presented from Phase I/II Allovectin-7 Trial

Published in Gene Therapy Weekly, April 3rd, 1995

Scientists from the University of Arizona and Vical Inc., San Diego, California, presented the results of laboratory tests on patients enrolled in the company's Phase I/II clinical trial of its cancer immunotherapy product candidate, Allovectin-7, in two papers at the 86th Annual Meeting of the American Association for Cancer Research (AACR), held in Toronto, Ontario, Canada, March 17-22, 1995.

Allovectin-7 is a gene-based product intended for direct injection into tumor lesions of cancer patients. The product contains a gene that encodes a mismatched transplantation antigen (HLA-B7) which, when injected into tumors, is intended to cause the malignant cells to bear the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1995-04-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry